• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Medical Tubing and Extrusion

Medical tubing and extrusion technologies

  • Technologies
    • Balloons
    • Brain-computer interfaces
    • Cardiac Implants
    • Catheters
    • Endoscopes
    • Heart valves
    • Pulsed Field Ablation
  • Components
    • Connectors
    • Needles and Injections
    • Seals
    • Tubing Components
  • Manufacturing
    • Coatings
    • Extrusions
    • Machining
    • Molding
      • Injection Molding
      • Insert molding
      • Mold Components
    • Tools
  • Materials
    • Advanced Materials
    • Metals
    • Nitinol
    • Plastics
    • Silicone
  • Business
    • Distribution Agreements
    • Legal News
    • Mergers & Acquisitions
    • Partnerships
    • Personnel Moves
  • Regulatory
    • 510(k)
    • CE Mark
    • FDA Breakthrough Designation
    • ISO Certification
    • Pre-Market Approval (PMA)
    • Recalls
  • Suppliers
  • About Us

Jupiter Endovascular completes enrollment in Vertex pulmonary embolectomy trial

February 4, 2026 By Sean Whooley

Jupiter Endovascular Vertex Pulmonary Embolectomy System
The Vertex pulmonary embolectomy system. [Image courtesy of Jupiter Endovascular]
Jupiter Endovascular announced today that it completed patient enrollment in the SPIRARE II pivotal clinical trial evaluating its Vertex system.

SPIRARE II evaluates the Vertex pulmonary embolectomy system in patients with acute, intermediate-risk pulmonary embolism (PE). Dr. Vikas Aggarwal, interventional cardiologist at Henry Ford Hospital and the site’s principal investigator, enrolled the final subject.

The prospective study enrolled 123 patients across 23 sites in Europe and the U.S. It follows the SPIRARE I trial, for which Menlo Park, California-based Jupiter reported results last fall. Endpoints for SPIRARE II characterize the procedural and clinical performance of PE treatment with the Vertex system. They span measures of safety, right heart function and clinical improvement from the time of the procedure to 30 days post-procedure.

Learn more about Vertex from an interview with a co-inventor in our free-to-download Min-Vasive Medtech Special Report at Medical Design & Outsourcing.

Vertex incorporates Jupiter’s novel transforming fixation (TFX)  technology into an endovascular procedure. It designed the technology to treat acute pulmonary embolism (PE) with control and precision.

The system delivery takes place in a flexible, relaxed state over a guidewire to a target location in the vasculature. Rapidly pressurized with saline, it fixes in a stable position for intervention. Then, it returns to a relaxed state to navigate to another target location or for removal. The system received FDA investigational device exemption in August 2024.

Jupiter won FDA clearance for its Vertex catheter incorporating TFX in September 2025, then announced $40 million in funding weeks later.

“Completing enrollment in SPIRARE II is a testament to the dedication of our investigators and the strength of the clinical hypothesis underlying the use of TFX in treating pulmonary embolism,” said Carl J. St. Bernard, CEO of Jupiter Endovascular. “We believe PE thrombectomy must evolve beyond simply debulking thrombus to reliably restoring hemodynamics and supporting cardiac recovery. SPIRARE II is designed to generate data to support that shift and to demonstrate the clinical promise of TFX technology in treating diseases residing in complex cardiovascular anatomies.

“We would like to thank the physicians, researchers, and patients across the U.S., Poland, Austria, and Switzerland whose commitment and participation made this study possible. We look forward to presenting the trial results later this year.”

Filed Under: Applications, Cardiology, Catheters, Technologies & Devices Tagged With: Jupiter Endovascular

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“mte
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest trends and developments in medical tubing and extrusion.
MDO ad

Sponsored Content

A new way to access scientific papers?

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Inv Logo

MASSDEVICE MEDICAL NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World
Drug Delivery Business News

Medical Tubing + Extrusion

Subscribe to our E-Newsletter
Advertise with us
About
Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | RSS